Replies to post #169134 on Vivos Inc (RDGL)

[wrinklesobw]

They do have around 1.5-1.8 million cash on hand which in my opinion should be enough to get through phase 1 clinical trials. If they get ide approved and can start asap.

However they did just do an offering at .065 to raise around 3.2 million dollars. Which is odd because they just amended an existing offering just a few weeks ago.
So Right now there’s a few confusing things going on right now. Why the new offering for less and why was it done just a few weeks after the amendment.

If you haven’t figured out don’t believe a couple of posters on here. They have a personal agenda and even if you ask a question they don’t answer directly or at all.

Lots of longs invested here and unfortunately some of have been here for 5 plus years. Nuts I know. In short there’s every bit of 100 million shares held in longs hands.

[kayak_wench]

We do not have sufficient funding for the human clinical trials. As noted in 10Qs and 10-Ks for sometime the company has been tossing around a cost of $9 million to complete everything they need to get the device approved, Isopet clinics across the country, create an independent production center, and get started on having approvals for non-US markets. What they have told us is they had sufficient funds in the bank to submit the IDE. They have tended to build up their cash reserves a few months before they need it, so the recent offering should be for expenses related to items/things being done after the IDE submission rather than before. But things can change and if they do Koreko's plans may need to change with them (like FDA wanting more rabbits tested).

They will probably sell into the news of IDE submission and acceptance. They did that with the news of BDD submisson and generated enough money to get through most of the IDE application development.